AOverview
Arthrex is a private medical device company that specializes in arthroscopy and sports medicine. It develops and distributes tools, implants, and technologies used in minimally invasive joint surgery, with a focus on educating surgeons and expanding surgical techniques. The company’s products enable doctors to perform arthroscopic procedures through small incisions, using specialized instruments and implants designed for precision and repair inside joints. Unlike many competitors, Arthrex remains privately held to reinvest in research and development, pursue long-term innovation, and avoid quarterly profit pressures. Its goal is to help surgeons treat their patients better by advancing orthopedic care through continuous education and a broad catalog of surgical solutions used globally.
Work here?Claim your company
About Arthrex
Industries
Company Size
5,001-10,000
Company Stage
Early VC
Total Funding
$2.2M
Headquarters
Naples, FL
Founded
1981
Get referred to Arthrex
See people who can refer or advise you
Simplify's take
What believers are saying
- Arthrex expanded Ave Maria manufacturing through 2026, adding warehouse and childcare capacity.
- TightRope SB launched in 2026 with radiopaque all-suture fixation and early U.S. adoption.
- The 2026 ICRS partnership strengthens cartilage restoration and joint preservation credibility.
What critics are saying
- Stryker, J&J, and Zimmer Biomet are targeting Arthrex's foot and ankle categories.
- FDA clearance pending on ACFAS 2026 products creates launch slippage and reimbursement risk.
- A product-quality or recall crisis would damage surgeon trust and threaten Arthrex's private moat.
What makes Arthrex unique
- Arthrex sells procedure-specific implants, education, and 3DAnatomy training together.
- On 2026-11-08, Arthrex showcased TightRope PRO, Lapidus I-Beam, and BunionBrace at ACFAS.
- Arthrex still stays private, funding factories like Ave Maria and surgeon education internally.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$2.2M
Above
Industry Average
Funded Over
1 Rounds
Growth & Insights and Company News
6 month growth
0%1 year growth
13%2 year growth
13%Arthrex Ankle innovation named "Coolest Thing Made in Florida" The Syndesmosis TightRope PRO implant builds on more than 20 years of TightRope technology, with earlier iterations being used to treat hundreds of thousands of patients, including former NFL tight end Kyle Rudolph and current NFL quarterback Riley Leonard. After months of voting and five head-to-head rounds against some of the most innovative products manufactured in the Sunshine State, the Arthrex Syndesmosis TightRope(R) PRO implant has officially been named the 2026 Coolest Thing Made in Florida. The Syndesmosis TightRope PRO implant builds on more than 20 years of TightRope technology, with earlier iterations being used to treat hundreds of thousands of patients, including former NFL tight end Kyle Rudolph and current NFL quarterback Riley Leonard. Always striving for more minimally invasive and reproducible surgical techniques, the idea for the TightRope PRO device took shape with a design that includes integrated suture tensioning handles and lower-profile button implants that allow for smaller bone-conserving drill tunnels. Arthrex's commitment to innovation in Ankle surgery. "[Sr. Product Manager] Andrew Rullan and I came to the first TightRope PRO meeting with 3D printed prototypes made by [Industrial Designer Principal] Mark Shainwald," said Engineering Supervisor Steven Iden. "We knew we liked the concept, but we had no idea if it was manufacturable or scalable for broad clinical use." The product was the result of close collaboration across multiple Arthrex teams, including Engineering, Manufacturing, Quality Assurance and Operations. "It was nice to see the TightRope PRO from the ground up," said Production Coordinator Jennifer Becker. "As a group, we went over the design, talked through details, brainstormed and suggested some changes to the original design concept." "The TightRope PRO represents a great success story of using the design for manufacturing methodology to arrive at an award-winning product," said Sr. Manager of Manufacturing Engineering Tracy Fields. "I've been part of developing a lot of different products, and I'm proud of what we came up with for this one." "We have to be very precise, but I enjoy it," said Suture Assembly Operator III Leyda Rios. "I'm proud to be making this. I read the stories we share online about Arthrex products helping everyone from our family members to high-profile athletes; it's amazing to think about where this might end up." "The TightRope PRO presented us with the opportunity to make a proven product smaller, faster and better," said Steven. "[President and Founder] Reinhold Schmieding, [Engineering Director] Michelle Morar and [Director of Foot & Ankle and Trauma Product Management] Michael Karnes gave us everything we needed to get it done, and I think this product is a great representation of Arthrex, where teams are always working together to make cool products that are Helping Surgeons Treat Their Patients Better(R)." "Let's go! What an incredible honor and truly a testament to the work that has gone into making this product," said Andrew, who was among the group of Arthrex employees who traveled to the Florida Chamber's Future of Florida Forum and Annual Meeting in Orlando to accept the 2026 Coolest Thing Made in Florida award. "I'm extremely proud of the teams who have made this all possible. This award is a representation of the innovative work Arthrex is doing day in and day out!" Arthrex extends its thanks to the employees, surgeons and partners who have contributed to the development, manufacture, education and distribution of TightRope PRO and to everyone who supported the product throughout the competition.
Arthrex wins! TightRope(R) PRO officially named the 2026 Coolest Thing Made in Florida. Arthrex Arthrex Syndesmosis TightRope PRO smaller bone-conserving drill tunnels After months of voting and five head-to-head rounds against some of the most innovative products manufactured in the Sunshine State, the Arthrex Syndesmosis TightRope(R) PRO implant has officially been named the 2026 Coolest Thing Made in Florida. The Syndesmosis TightRope PRO implant builds on more than 20 years of TightRope technology, with earlier iterations being used to treat hundreds of thousands of patients, including former NFL tight end Kyle Rudolph and current NFL quarterback Riley Leonard. Always striving for more minimally invasive and reproducible surgical techniques, the idea for the TightRope PRO device took shape with a design that includes integrated suture tensioning handles and lower-profile button implants that allow for smaller bone-conserving drill tunnels. "[Sr. Product Manager] Andrew Rullan and I came to the first TightRope PRO meeting with 3D printed prototypes made by [Industrial Designer Principal] Mark Shainwald," said Engineering Supervisor Steven Iden. "We knew we liked the concept, but we had no idea if it was manufacturable or scalable for broad clinical use." The product was the result of close collaboration across multiple Arthrex teams, including Engineering, Manufacturing, Quality Assurance and Operations. "It was nice to see the TightRope PRO from the ground up," said Production Coordinator Jennifer Becker. "As a group, we went over the design, talked through details, brainstormed and suggested some changes to the original design concept." "The TightRope PRO represents a great success story of using the design for manufacturing methodology to arrive at an award-winning product," said Sr. Manager of Manufacturing Engineering Tracy Fields. "I've been part of developing a lot of different products, and I'm proud of what we came up with for this one." "We have to be very precise, but I enjoy it," said Suture Assembly Operator III Leyda Rios. "I'm proud to be making this. I read the stories we share online about Arthrex products helping everyone from our family members to high-profile athletes; it's amazing to think about where this might end up." "The TightRope PRO presented us with the opportunity to make a proven product smaller, faster and better," said Steven. "[President and Founder] Reinhold Schmieding, [Engineering Director] Michelle Morar and [Director of Foot & Ankle and Trauma Product Management] Michael Karnes gave us everything we needed to get it done, and I think this product is a great representation of Arthrex, where teams are always working together to make cool products that are Helping Surgeons Treat Their Patients Better(R)." "Let's go! What an incredible honor and truly a testament to the work that has gone into making this product," said Andrew, who was among the group of Arthrex employees who traveled to the Florida Chamber's Future of Florida Forum and Annual Meeting in Orlando to accept the 2026 Coolest Thing Made in Florida award. "I'm extremely proud of the teams who have made this all possible. This award is a representation of the innovative work Arthrex is doing day in and day out!" Arthrex extends its thanks to the employees, surgeons and partners who have contributed to the development, manufacture, education and distribution of TightRope PRO and to everyone who supported the product throughout the competition. The De Angelis Group | Orthopedics This Week | MSK Innovations Why This Matters Two perspectives. MBA Lens: Economic and industry impact. Arthrex's Syndesmosis TightRope(R) PRO, an evolution of its 20-year-old TightRope technology, secured the "2026 Coolest Thing Made in Florida" award. This win highlights Arthrex's strategy of continuous innovation, focusing on enhancing proven products with features like smaller drill tunnels and integrated tensioning. The company's collaborative development process and commitment to minimally invasive solutions aim to drive broad clinical adoption and reinforce its market leadership in trauma and foot & ankle. * The TightRope PRO's design, emphasizing smaller bone-conserving drill tunnels and integrated tensioning, targets improved surgical reproducibility and patient outcomes. * This award underscores Arthrex's successful "design for manufacturing" approach and its strategy to continually refine established products for competitive advantage. PhD Lens: Clinical and outcomes impact. The Arthrex Syndesmosis TightRope(R) PRO implant, building on two decades of TightRope technology, was recognized as the "2026 Coolest Thing Made in Florida." Its design incorporates integrated suture tensioning handles and lower-profile button implants, facilitating smaller bone-conserving drill tunnels. This aims to achieve more minimally invasive and reproducible surgical techniques, representing an advancement in syndesmosis repair. Development involved 3D printed prototypes and cross-functional team collaboration. * The device's mechanism focuses on enhancing surgical precision and bone conservation through its refined implant profile and tensioning features. * While an evolution of a widely used technology, the article does not present new clinical evidence or specific material science details for the PRO version. Discussion. Dr. Sarah Mitchell Orthopedic Surgeon · Mayo Clinic This is a fascinating development. In my practice Orthopedics This Week Inc. has seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds? James Thornton, MD Spine Fellow · HSS Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT. R. Patel Sports Medicine · Stanford Orthopedics This Week Inc. implemented a similar approach last year. Early results are promising but Orthopedics This Week Inc. is still gathering 12-month follow-up data. Happy to share its protocol if anyone is interested. Join the conversation. Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.
North America leads Foot and Ankle Reconstruction devices market. Foot and ankle problems don't get the attention that hip and knee replacements do, but the devices used to fix them - plates, screws, fusion systems, total ankle implants - are quietly becoming one of the more dynamic corners of orthopedics. Here's where the market stands and where it's headed. Market Size and Growth Metrics The global foot and ankle reconstruction devices market was valued at USD 1.8 billion in 2025 and is estimated to reach USD 1.9 billion in 2026. From there, it's projected to climb to USD 3.3 billion by 2033, growing at a CAGR of 8.3% between 2026 and 2033 - nearly doubling in under a decade. What's fueling that growth: * An aging population with degenerative joint disease. The CDC estimated roughly 33 million U.S. adults were living with osteoarthritis by the end of 2024, and the Osteoarthritis Action Alliance projects that figure will hit 72 million by 2030 and 78 million by 2040. Around 25% of ankle fractures in patients over 60 are linked to osteoporosis, and ankle osteoarthritis affects an estimated 3.4% of the global adult population - all of which translates into steady surgical demand. * Minimally invasive techniques going mainstream. Surgeons are shifting toward smaller incisions, faster recovery, and procedure-specific instrumentation for tendon repairs, fusions, and osteotomies. * Smarter surgical technology. Computer-assisted navigation, AI-driven imaging interpretation, and predictive planning tools are improving implant placement accuracy and reducing revision rates. By the numbers: * North America led all regions with a 47.9% revenue share in 2025, backed by strong reimbursement systems and high procedure volumes; the U.S. is the largest single country market. * Hallux valgus (bunion) correction was the top application segment at 31.4% share in 2025, though hammertoe correction is expected to grow fastest through the forecast period. * Hospitals captured 59.7% of end-use revenue in 2025, while outpatient/ambulatory surgical centers are the fastest-growing setting, as more elective reconstruction procedures move out of inpatient settings entirely. One notable headwind: regulatory complexity. Compliance with FDA requirements, EU MDR 2017/745, and region-specific approval pathways adds significant time and cost to bringing new implants to market - a burden that falls hardest on smaller manufacturers. Competitive Landscape and Core Players The market splits fairly cleanly into two tiers. Established multinational players - Stryker, DePuy Synthes (Johnson & Johnson), Zimmer Biomet, Smith+Nephew, and Arthrex - compete on scale: broad product portfolios spanning trauma, reconstruction, and sports medicine; deep clinical evidence; global distribution; and long-standing surgeon relationships. Their weakness is largely structural - premium pricing and complex regulatory overhead can limit adoption in cost-sensitive settings. Emerging and specialized players - Globus Medical, Orthofix, Enovis, Acumed, CONMED, and Anika Therapeutics - compete on agility, focusing on procedure-specific fixation systems, orthobiologics, and minimally invasive implants. They move faster on niche innovation but lack the global footprint and hospital procurement relationships of the majors. Recent activity shows both tiers pushing hard on product launches: * Stryker expanded its Foot & Ankle portfolio in the U.S. (September 2024) with the Osteotomy Truss System and Ankle Truss System for fusion and total ankle procedures. * DePuy Synthes launched the TriLEAP Lower Extremity Anatomic Plating System (August 2025) for forefoot and midfoot reconstruction. * Zimmer Biomet and Treace Medical Concepts both showcased updated bunion-correction and total ankle systems at the AOFAS Annual Conference in September 2025. * Fusion Orthopedics acquired Metalogix External Fixation Systems (January 2025), adding external fixation frames and mini-rail systems to its lineup - a sign that M&A activity, while moderate overall, is still reshaping portfolios. Competitive advantage increasingly hinges on demonstrable clinical outcomes and comprehensive, procedure-specific offerings that bundle implants, biologics, and digital surgical planning together, rather than any single device. Product Specifications and Innovation Highlights Reconstruction devices in this market are segmented by the specific anatomical problem they solve. Hallux Valgus/Bunion Correction devices include plates, screws, staples, and intramedullary fixation and osteotomy implants, all designed to realign the first metatarsal and great toe. Hammertoe Correction relies on intramedullary implants, fixation pins, screws, and fusion systems to realign and stabilize the affected interphalangeal joints. Midfoot Reconstruction uses fusion plates, locking screws, and compression staples to stabilize the tarsometatarsal and naviculocuneiform joints following trauma, arthritis, or Charcot foot. Hindfoot & Ankle Reconstruction devices - arthrodesis plates, intramedullary nails, locking screws, and compression systems - restore alignment and stability in severe arthritis, instability, or post-traumatic cases. Total Ankle Replacement (TAR) implants use prosthetic tibial and talar components to replace the damaged joint while preserving natural motion, offering an alternative to fusion for end-stage arthritis. Toe Joint Replacement systems, primarily targeting the first metatarsophalangeal (MTP) joint, use artificial joint implants to restore mobility and relieve pain in arthritic or degenerated toes. Some recent product specifics worth noting: * SINTX Technologies' SINAPTIC Foot & Ankle Osteotomy Wedge System (FDA-cleared October 2025) is made from silicon nitride, engineered specifically for hallux valgus precision. * Medline UNITE's REFLEX HYBRID Nitinol Implant System (FDA 510(k), April 2025) combines locking plate stability with nitinol staple compression for MTP fusions and Lapidus procedures. * Forma Medical's OptimalHT system (2023) brought dedicated minimally invasive instrumentation to hammertoe correction, a segment that had lagged behind bunion surgery in MIS adoption. * NovaBone's bioglass syringes (2.5cc/5cc) target bone defect repair and osseointegration as an adjunct to hardware-based fixation. The throughline across nearly every recent launch is anatomical specificity paired with less invasive delivery - implants engineered for one exact procedure rather than general-purpose hardware, combined with smaller incisions and faster weight-bearing timelines. This market rewards companies that can pair strong clinical data with genuinely differentiated, procedure-specific hardware - a pattern likely to hold as the patient population driving demand (older, more diabetic, more active later in life) continues to grow. Customize This Report - get 20% free customization to tailor scope, segments, or regions to your needs Matched content.
Council to vote on data Center moratorium as part of Tuesday's meeting. Greg Wilson/Anderson Observer Anderson County Council at 6:30 p.m. on Tuesday is expected to vote on the Center Rock zoning map, a proposed data-center moratorium, an economic-development incentive agreement, and the revival of the Savannah River National Scenic Byway. In an unusual move, the regular meeting is connected to a pair of moves at the earlier 6 p.m. proclamations and recognitions meeting. Council is expected to proclaim Sept. 22 as National Scenic Byway Day and formally recognize the 110-mile Savannah River National Scenic Byway, including Anderson County's 39-40-mile stretch that includes Hartwell Lake and Green Pond Landing. Council is also set to honor Pendleton Recreation Association's 12U baseball team for its state championship and World Series appearance, as well as the association's 8U All-Star team for winning a district title. The regular meeting includes four public hearings and final votes on major measures: adopting the zoning map approved by Center Rock Precinct voters, who backed zoning in an Aug. 11 referendum by a 452-95 margin; final action on a six-month moratorium on new data-center applications while county officials develop regulations addressing the industry's effects on utilities, water, infrastructure, and nearby property owners; and a proposed fee in lieu and special-source-credit agreement with for an expansion at Arthrex, which is proposing a new $28.2 million investment with 63 new full-time jobs. On first reading, council will consider rezoning 91.65 acres on Dixon Road in the Centerville Station A Precinct from I-2 Industrial Park to R-20 Single-Family Residential. It will also vote on Project Palmetto, a proposed industrial project promising to deliver at least $215.56 million in investment and create at least 217 jobs, through a proposed fee-in-lieu-of-tax agreement and inclusion in a joint Anderson-Greenville industrial park.
Hassan Usmani, a podiatric surgeon at Lakeshore Bone & Joint Institute in Indiana, has become the first surgeon in the state to perform a procedure using the Arthrex Lapidus I-Beam Plate and BunionBrace system. The surgery was completed at Lakeshore Surgicare, an ambulatory surgery centre in Chesterton. The Arthrex system is a minimally invasive, joint-preserving option designed to correct bunion deformities by securing bones in their corrected position and reinforcing the medial capsule. The technology aims to restore big toe alignment, reduce pain and support natural foot function. The procedure is intended for patients seeking alternatives to more invasive bony procedures, particularly when conservative management has proven inadequate. Lakeshore Bone & Joint Institute has served northwest Indiana since 1968.
There are no jobs for Arthrex right now.
Find jobs on Simplify and start your career today
We update Arthrex's jobs every few hours, so check again soon!Browse all jobs
About Arthrex
Industries
Company Size
5,001-10,000
Company Stage
Early VC
Total Funding
$2.2M
Headquarters
Naples, FL
Founded
1981
There are no jobs for Arthrex right now.
Find jobs on Simplify and start your career today
We update Arthrex's jobs every few hours, so check again soon!Browse all jobs